OncoImmunology (Jan 2018)

TNFR2: The new Treg switch?

  • José L. Cohen,
  • Kathryn J. Wood

DOI
https://doi.org/10.1080/2162402X.2017.1373236
Journal volume & issue
Vol. 7, no. 1

Abstract

Read online

Three recent publications identified the TNF/TNR2 pathway as a new target to reduce graft-versus-host-disease through regulatory T cells activation or to potentially switch on a strong anti-leukemic effect through regulatory T cells blockade in allogeneic hematopoietic stem cell transplantation. This identified the TNF/TNR2 pathway as a swith and as a new target for immune checkpoint therapy to modulate the immune regulation in this clinical setting.

Keywords